Keywords chronic obstructive pulmonary disease, diuretics, health administrative database research, health outcomes research, pharmacoepidemiology AIMS Diuretic drugs may theoretically improve respiratory health outcomes in chronic obstructive pulmonary disease (COPD) through several possible mechanisms, but they might also lead to respiratory harm. We evaluated the association of incident oral diuretic drug use with respiratory-related morbidity and mortality among older adults with COPD.
Introduction
More than 10% of individuals aged 40 years and older around the globe are estimated to have chronic obstructive pulmonary disease (COPD) [1] . Cardiovascular comorbidity [2, 3] and persisting respiratory symptoms despite maximal conventional therapy [4, 5] commonly occur in COPD. As a result, diuretic drugs may be prescribed in COPD for a variety of reasons: pulmonary hypertension and cor pulmonale; pulmonary oedema; systemic hypertension; and empirically for severe dyspnoea refractory to maximal conventional therapy. Diuretic drugs may theoretically improve respiratory health outcomes in COPD through several possible mechanisms. Diuretics may reduce pulmonary hypertension (either subclinical or overt) and cor pulmonale by decreasing preload to the heart and they can also reduce pulmonary oedema. The presence of pulmonary hypertension in COPD is associated with increased mortality risk [6] and symptoms related to excessive fluid overload may lead an individual with COPD to present to hospital for acute care [7] . Acetazolamide (a specific type of diuretic drug) is also known to have respiratory stimulant properties. Acetazolamide inhibits the renal carbonic anhydrase enzyme, which reduces serum bicarbonate and contributes to metabolic acidosis, which in turn increases minute ventilation through peripheral and central chemoreceptor stimulation [8] . By stimulating minute ventilation and improving gas exchange, acetazolamide may mitigate dyspnoea crises and respiratory exacerbations among individuals with COPD.
However, use of diuretic drugs may also lead to respiratory-related harm among individuals with COPD. With the exception of acetazolamide, all other diuretic drugs (and particularly loop diuretics) have the potential to increase serum bicarbonate and arterial pH, which can then dampen peripheral and central chemoreceptor activity. Hypercapnia, which can occur as a result, is associated with increased risks of respiratory exacerbation [9] and mortality [9] [10] [11] . Another potential complication of nonpotassium sparing diuretic drug use is hypokalaemia, which is known to be linked to potential respiratory muscle weakness and acute respiratory failure [12, 13] . There are minimal and conflicting data regarding the potential respiratory effects of diuretic drugs among individuals with COPD [14] [15] [16] [17] [18] [19] , with few previous studies focusing on systemic formulation diuretics [18, 19] and clinically important respiratory health outcomes [19] . The purpose of this study was to evaluate the association of new oral diuretic use with respiratory-related morbidity and mortality among older adults with COPD.
Methods

Study design
This was a retrospective cohort study using health administrative data from Ontario, Canada, from 1 April 2008 to 30 April 2013. Ontario is Canada's most populous province (13.5 million people); it is culturally diverse and it has a universal, single-payer health care system. The review ethics board at Sunnybrook Health Sciences Centre approved this study.
Data sources
Thirteen Ontario health administrative databases at the Institute for Clinical Evaluative Sciences (ICES) in Toronto, Ontario, Canada were linked at an individual person level using unique coded identifiers. COPD health administrative codes were previously validated [20] and a database of individuals with physician-diagnosed COPD was created. For this study, a highly-specific algorithm of health administrative codes was used to identify COPD diagnosis: three or more ambulatory claims for COPD within any 2-year period or one or more hospitalization(s) for COPD (specificity 95.4% [95% confidence interval (CI) 92.6-97.4%]; sensitivity 57.5% [95% CI 47.9-66.8%]) [20] . All publicly-funded outpatient medication dispensed to Ontarians aged 65 years and older are recorded in the Ontario Drug Benefit (ODB) database. The ODB has very low drug claim coding error at 0.7% (95% CI 0.5-0.9%) [21] . The Ontario Health Insurance Plan claims database contains information on patient contact with physicians in both ambulatory and hospital settings, the National Ambulatory Care Reporting System database contains information on emergency room (ER) visits and the Canadian Institute for Health Information (CIHI) Discharge Abstract Database contains information on hospitalizations. The Registered Persons Database contains information on mortality and cause of death data are recorded in the Office of the Registrar General -Deaths database. All other health administrative databases used are described in the Supporting Information.
Study population
To be included in the study, individuals had to meet all the following criteria between 1 April 2008 to 31 March 2013: have validated physician-diagnosed COPD; be an Ontario resident; and be age 66 years or older. Those receiving palliative care (based on physician service codes) in the year prior to the index date (defined below) were excluded to minimize potential bias, as such individuals may be more likely to receive diuretics and have high likelihood of poor outcomes.
Exposed and control groups with index date definitions Exposed group. All oral diuretic drugs considered in this study are listed in the Supporting Information. Only oral formulations were included, since intravenous agents are unlikely to be used in the outpatient setting. Diuretic drug users were defined by incident use of any diuretic drug (regardless of whether the diuretic was on its own or combined with another drug in a single pill) between 1 April 2008 and 31 March 2013. Although some diuretic drugs were combined with another cardiac medication in a single pill, we ensured that exposed and control individuals were well-balanced on receipt of nondiuretic cardiac drugs (see below). Incident use was defined as no diuretic drug receipt in the year prior to the incident date. Prevalent drug use was not considered to minimize healthy user bias and since our purpose was to examine for acute-onset drugrelated events. If criteria for incident drug use were met more than once during the study, only the first dispensing was considered, and an exposed individual was not allowed to cross-over to the control group at any time. The index date for exposed individuals was the date the incident diuretic was dispensed.
Control group. Controls did not receive any diuretic drug between 1 April 2008 and 31 March 2013. We elected to define control group entry by a drug exposure, since exposed group entry involved drug receipt. Using a similar approach as previous [22, 23] , control group entry was defined as the most recent of any incident nondiuretic medication claim on or before a date chosen randomly from the accrual period. Incident nondiuretic drug use was defined as no receipt of a drug within the same class as the index nondiuretic drug in the year prior to the incident date. If the most recent nondiuretic drug dispensing took place >6 months before the randomly selected date from the accrual period, or if it took place before the start of the 2008-2013 period, then the individual was excluded. The index date for control individuals was the date the incident nondiuretic drug was dispensed.
Study outcomes
The primary outcome was hospitalization for COPD or pneumonia within 30 days after the index date, since this is a common and clinically-important complication of COPD, associated with significant morbidity and mortality [7, 24] . Other outcomes examined within 30 days after the index date included: outpatient respiratory exacerbations (defined similar to previous [22, 23] as oral corticosteroid or respiratory antibiotic receipt within ±7 days of a physician clinic/office visit for COPD or pneumonia, with the corticosteroid or antibiotic prescription having a supply of 5-21 days); ER visits for COPD or pneumonia that did not directly result in a hospitalization; admission to an intensive care unit (ICU) during a hospitalization for COPD or pneumonia; COPD or pneumonia-related mortality; and, all-cause mortality. COPD and pneumonia diagnoses were based on relevant International Classification of Diseases (ICD) codes (e.g., in ICD-10: J41, J42, J43, J44 for COPD; J09-18, J20-22, J40 for pneumonia). A 30-day follow-up period was selected, since we found this to be the mean duration of incident diuretic dispensing and since our intention was to evaluate for acute-onset drug-related benefits or harms.
Propensity score weighting
We anticipated exposed individuals to differ from controls on demographic and health characteristics that would influence risk of diuretic receipt and subsequent respiratory outcomes. Therefore, inverse probability of treatment weighting using the propensity score [25, 26] was employed to create weighted samples of exposed and control individuals, where measured baseline covariates were balanced between the two groups. A propensity score for new diuretic receipt was developed using logistic regression modelling with 55 different covariates, including markers of COPD severity, health care use, comorbidities, other cardiac and noncardiac medication receipt and demographic variables. The full list of variables included in the propensity score can be found in the Supporting Information and an abridged list is shown in Table 1 .
Sensitivity analyses
First, we evaluated our outcomes stratifying by COPD exacerbation history in the year prior to the index date (defined as a three-level, mutually-exclusive variable: no exacerbation vs. one or more outpatient exacerbation with no exacerbation requiring presentation to hospital vs. one or more exacerbation requiring presentation to hospital). COPD exacerbation history is an important marker of disease severity, as it is associated with a greater degree of airflow obstruction [27] , poorer quality of life [28] , future exacerbation risk [29] and mortality [30] . Previous COPD exacerbation is known to be the strongest predictor of future exacerbation [29] , and Canadian [24] and newer global [7] COPD guidelines use COPD exacerbation frequency to distinguish COPD severity. Evaluating for outcomes across subgroups of differing COPD severity helps minimize possible "healthy user" bias (by examining outcomes in the sickest subgroup of patients) and confounding by indication (by examining outcomes in the healthiest subgroup of patients).
Second, outcomes were examined stratifying by whether or not congestive heart failure (CHF) was present within 5 years prior to the index date. The purpose of this analysis was to minimize possible confounding by indication, by evaluating outcomes in the healthier subgroup of individuals without pre-existing CHF.
Third, we examined outcomes distinguishing by the type of diuretic received (i.e., loop diuretic vs. potassium-sparing diuretic vs. thiazide diuretic vs. carbonic anhydrase inhibitor -see Supporting Information for a list of diuretic drugs by subclasses). The purpose of this analysis was to Finally, we performed a sensitivity analysis where we evaluated our adverse respiratory outcomes among new diuretic users [who were not concomitantly receiving angiotensin converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) drugs] vs. new ACEI/ARB users (who were not concomitantly receiving diuretic drugs). The purpose of this final analysis was to help further minimize possible confounding by indication and potential outcome misclassification (between respiratory and cardiac events), as both diuretic and ACEI/ARB drugs may be prescribed for cardiovascular reasons, and in contrast to diuretics, ACEI/ARB drugs are not associated with potential complications of metabolic alkalosis or hypokalaemia. Similar to our main analyses, incident diuretic (or ACEI/ARB) use was defined as no diuretic (or ACEI/ARB) drug receipt in the year prior to the incident date. Concomitant diuretic (or ACEI/ARB) use was defined as a dispensing for a diuretic (or ACEI/ARB) drug within 90 days prior to the index date (i.e. the date of incident drug receipt). The propensity score was re-estimated for each of our sensitivity analyses.
Statistical analysis
Descriptive statistics and standardized differences for the exposed and control groups on all baseline covariates were calculated before and after propensity score weighting [26] . Since we examined for multiple, potentially competing outcomes, Cox proportional hazard regression modelling with a robust variance estimator was used to estimate a hazard ratio (HR) with associated 95% confidence interval (CI) for each outcome in the propensity score weighted samples [31] . Since an individual theoretically may have experienced any of our nonmortality outcomes more than once during the follow-up period, we also estimated a rate ratio with associated 95% CI for nonmortality outcomes using Poisson regression with generalized estimating equations methods [32] (this analysis is presented in the Supporting Information). All statistical analyses were conducted using SAS Enterprise Guide 6.1 (SAS Institute Inc., Cary, NC, USA). Two-sided tests of significance at the P < 0.05 level were used. (Table 1 and Supporting Information). The most commonly prescribed diuretic type was loop diuretics (58.6%), followed by thiazides (38.4%), potassium-sparing (5.8%) and anhydrase inhibitors (2.0%). After propensity score weighting, baseline characteristics were well-balanced between exposed individuals and controls, with standardized differences below 10% for all variables (Table 1 and Supporting Information).
Results
Overall cohort results
Out of
Compared to controls, recipients of incident diuretics had significantly increased rates for hospitalizations for COPD or pneumonia (HR 1.22, 95% CI 1.07-1.40; Table 2 ). ER visits for COPD or pneumonia (HR 1.35, 95% CI 1.18-1.56), COPD or pneumonia-related mortality (HR 1.41; 95% CI 1.04-1.92) and all-cause mortality (HR 1.20, 95% CI 1.06-1.35) were also greater among incident diuretic users. No significant associations were observed between diuretic use and outpatient respiratory exacerbations or admissions to ICU.
Sensitivity analyses
By COPD exacerbation history. Among individuals with no exacerbation in the year prior to the index date, new users had increased rates of hospitalizations for COPD or pneumonia (HR 1.44, 95% CI 1.17-1.76; Table 3 ). ER visits for COPD or pneumonia (HR 1.55, 95% CI 1.22-1.97), COPD or Table 2 Hazard ratios and 95% confidence intervals for outcomes in the propensity score weighted cohort Table 3 Hazard ratios and 95% confidence intervals for outcomes in the propensity score weighted cohort, stratified by COPD exacerbation frequency 
Discussion
Our large, population-based cohort study showed the novel finding that incident diuretic drug use (particularly use of loop diuretics) among older adults with COPD is associated with increased rates of respiratory-related morbidity and mortality. Our overall findings are strengthened by the fact that we observed negative respiratory outcomes with diuretic use even in healthier subgroups of individuals with COPD (such as those without history of respiratory exacerbation and those without pre-existing CHF) and when the comparison group was new drug use with a similar prescribing indication (i.e. ACEI/ARB use).
Table 4
Hazard ratios and 95% confidence intervals for outcomes in the propensity score weighted cohort, stratified by pre-existing known congestive heart failure CHF, congestive heart failure; CI, confidence interval; COPD, chronic obstructive pulmonary disease; ER, emergency room; HR, hazard ratio; ICU, intensive care unit Table 5 Hazard ratios and 95% confidence intervals for outcomes in the propensity score weighted cohort, distinguishing by diuretic drug type received Data on the potential respiratory effects of systemic formulation diuretic drugs in COPD have been minimal and conflicting. Diuretics have been shown to improve certain clinical parameters in COPD, such as plasma brain natriuretic peptide level and pulmonary artery pressure [18] . A randomized controlled trial of patients with COPD in the ICU receiving intravenous actezolamide 500-1000 mg daily vs. placebo found no significant difference in the duration of mechanical ventilation or weaning duration [19] . In contrast to our study, none of the aforementioned trials reported increased risk for adverse respiratory outcomes in association with diuretic use. However, some previous trials did not evaluate for possible drug-related adverse events [18] or were unable to detect them because they enrolled small numbers of selected individuals and tested limited drug doses and duration [18] . In contrast, our study incorporated large numbers of individuals, including those vulnerable to potential drug side-effects that clinical trials typically exclude (e.g. the elderly and individuals with comorbidities), evaluated real-world diuretic drug use and examined for clinically-important outcomes. The fact that diuretic drugs are known to potentially contribute to metabolic alkalosis with consequent hypercapnia and hypokalaemia, provides a rationale for why adverse respiratory events may have occurred.
We observed increased respiratory-related morbidity and mortality in association with diuretic use among healthier COPD subgroups, such as those without history of respiratory exacerbation and those without pre-existing CHF. We also found increased respiratory-related morbidity and mortality associated with new diuretic use when compared to new ACEI/ARB use, which is noteworthy as both drug groups would be prescribed for similar reasons and recipients of both drug groups would be at increased risk of acute cardiac events, which might masquerade as acute respiratory events. All the aforementioned subgroup analysis results strengthen our overall finding of an association between incident diuretic use and negative respiratory events. Although adverse respiratory events were not found to be elevated among new diuretic users with previous respiratory exacerbation requiring presentation to hospital (and these individuals would probably be more susceptible to negative outcomes), this may be related to selective diuretic prescribing in this sicker group, possibly out of concern for contributing to hypercapnia or other adverse event (e.g. dehydration). While adverse respiratory events were also not observed among the sicker subgroup of individuals with pre-existing CHF, this may be explained by the fact that diuretic drugs were reasonably prescribed in these individuals given their CHF and cardiac-related benefits were derived from therapy. The fact that incident diuretic drug receipt was associated with respiratory harm across a spectrum of outcomes (i.e. ER visits, hospitalizations and death) also supports the robustness of our findings. While the absolute adverse event rate increases were relatively small, they may be clinically important at the population level, as upwards of 10% of Ontario's population over age 35 years is estimated to have COPD [33] and over 50% of our COPD cohort was found to be receiving diuretic drugs.
Loop diuretic use drove the overall association with adverse respiratory events and this may be as a result of this drug subclass' well-known potential to cause metabolic alkalosis (which in turn can contribute to hypercapnia) and hypokalaemia. While thiazides and carbonic anhydrase inhibitors were not found to be associated with increased rates of negative respiratory events, these drug classes are less likely to cause metabolic alkalosis, as thiazides have relatively weak diuretic ability and are used more as antihypertensives and carbonic anhydrase inhibitors usually contribute to metabolic acidosis. Potassium-sparing diuretics may not have been associated adverse respiratory events because they protect from hypokalaemia. Although carbonic anhydrase inhibitor receipt was not found to protect from adverse respiratory events, this subgroup analysis may have been underpowered to detect such a benefit due to small sample sizes.
Although our analyses were adjusted for 55 covariates and we demonstrated increased rates of adverse respiratory events in association with diuretic use in healthier COPD subgroups and when compared to use of another drug class with similar prescribing indication, we cannot exclude confounding by Table 6 Hazard ratios and 95% confidence intervals for outcomes in the propensity score weighted cohort with new ACEI/ARB users serving as the control group For instance, a physician may see a patient with COPD who is struggling with dyspnoea, and, after all else fails, they may prescribe a trial of a loop diuretic to see if the diuretic improves the patient's respiratory status, whether or not the patient has a history of CHF. Similarly, if a COPD patient develops right heart failure with peripheral oedema, this may also prompt an incident prescription for a diuretic. In both cases, the patient had a pre-existing increased risk for respiratory-related morbidity and mortality, with the diuretic prescription serving as a marker of a sicker patient, and not being the causal factor behind the patients' possible subsequent poor outcome. We may also not have excluded all individuals receiving palliative care in the year prior to the index date using physician service codes. If some individuals receiving palliative care remained, confounding by indication may have contributed to increased rates of death observed among diuretic users. However, the possible residual inclusion of individuals receiving palliative care would unlikely explain the greater rates of respiratory-related outpatient exacerbations, ER visits and hospitalizations among diuretic recipients. Finally, while our COPD definition was highly specific (so we could be certain that individuals included in our study truly had COPD), it had modest sensitivity [20] , so our findings may not be generalizable to the entire older adult nonpalliative COPD population.
In conclusion, incident diuretic drug use (and specifically, loop diuretic receipt) was associated with increased rates of respiratory-related morbidity and mortality among older adults with nonpalliative COPD. Our study exposes a potential for adverse respiratory outcomes in association with diuretic drug administration in this population. However, further studies are needed to confirm if our results are causal or due to residual confounding.
Supporting Information
Additional Supporting Information may be found online in the supporting information tab for this article.
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